EXAMINING HEPATORENAL ALTERATIONS IN COVID-19 PATIENTS: IMPLICATIONS FOR SEVERITY AND MORTALITY
Main Article Content
Keywords
COVID-19 patients , biochemistry analyzer, non-survivors , uric acid
Abstract
Background: COVID-19 severity varies widely among individuals - from asymptomatic to acute respiratory distress cases (who require ventilation). The virus causes multi-organ damage, leading to significant variations in parameters controlled by these organs. We designed this study to check the effect of the COVID-19 virus on the hepatorenal health of patients.
Methods: Blood samples were collected from 240 COVID-19 patients (divided into Moderate=186 and Severe=54) and 89 healthy individuals, serving as controls. After a post-COVID-19 follow-up of two months, all the patients were categorized into survivors (212) and non-survivors (28). Hepatic (ALT, AST, ALP, Total Bilirubin and AST/ALT) and renal (Creatinine, Uric acid and Albumin) parameters were assessed using biochemistry analyzer. Statistical analysis was conducted using the student “t” test and One-Way ANOVA through GraphPad Prism software.
Results: Serum level of AST, ALT, ALP, and Total Bilirubin were considerably elevated in moderate and severe patient groups compared to the control group. Among the renal profiles, the serum creatinine level was also considerably higher (P=0.015). In contrast, Uric acid and albumin levels showed significant decrease in moderate and severe patient groups compared to the control group (P< 0.001). However, the comparison between survivors and non-survivors showed that serum AST, ALT, ALP, total bilirubin, and creatinine levels were significantly high for non-survivors. At the same time, uric acid and albumin levels were significantly low in non-survivors.
Conclusion: The hepatic and renal profiles exhibited alterations linked with COVID-19 severity and mortality. It is recommended to monitor these organs during hospitalization to prevent the risk of multiple organ damage, acute medical complications and death even after recovery from coronavirus disease.
References
2. Bielecka-Dąbrowa A, Cichocka-Radwan A, Lewek J, Pawliczak F, Maciejewski M, Banach M. 2021. Cardiac manifestations of covid-19. Reviews in Cardiovascular Medicine. 22(2).
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study. The lancet. 395(10223):507-513.
4. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. 2020. Kidney disease is associated with in-hospital death of patients with covid-19. Kidney international. 97(5):829-838.
5. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Wang C, Liu L. 2021. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nature communications. 12(1):2506.
6. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. 2020. Abnormal liver tests in covid‐19: A retrospective observational cohort study of 1,827 patients in a major us hospital network. Hepatology. 72(4):1169-1176.
7. McGrowder DA, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. 2021. Abnormal liver biochemistry tests and acute liver injury in covid-19 patients: Current evidence and potential pathogenesis. Diseases. 9(3):50.
8. Medetalibeyoglu A, Catma Y, Senkal N, Ormeci A, Cavus B, Kose M, Bayramlar OF, Yildiz G, Akyuz F, Kaymakoglu S. 2020. The effect of liver test abnormalities on the prognosis of covid-19. Annals of hepatology. 19(6):614-621.
9. Qian J-Y, Wang B, Liu B-C. 2020. Acute kidney injury in the 2019 novel coronavirus disease. Kidney diseases. 6(5):318-323.
10. Rudnick MR, Hilburg R. 2020. Acute kidney injury in covid-19: Another challenge for nephrology. American journal of nephrology. 51(10):761.
11. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J. 2020. Lancet infect dis. Elsevier Ltd.
12. Specific A. 2020. Expression in cholangiocytes may cause liver damage after 2019-ncov infection [preprint] chai x. Hu L, Zhang Y, et al bioRxiv.
13. Sultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB. 2020. Aga rapid recommendations for gastrointestinal procedures during the covid-19 pandemic. Gastroenterology. 159(2):739-758. e734.
14. Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z, Li H, Zheng M, Zhang N, Long C et al. 2020. Intercellular adhesion molecule-1 as target for car-t-cell therapy of triple-negative breast cancer. Front Immunol. 11:573823.
15. Wu Z, McGoogan JM. 2020. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in china: Summary of a report of 72 314 cases from the chinese center for disease control and prevention. jama. 323(13):1239-1242.
16. Xu L, Liu J, Lu M, Yang D, Zheng X. 2020. Liver injury during highly pathogenic human coronavirus infections. Liver international. 40(5):998-1004.
17. Xu Z. 2020. Shi l, wang y. Zhang J, Huang L, Zhang C, et al Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respir Med. 8:420-422.
18. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T. 2020. Clinical course and outcomes of critically ill patients with sars-cov-2 pneumonia in wuhan, china: A single-centered, retrospective, observational study. The lancet respiratory medicine. 8(5):475-481.
19. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. 2006. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes. Journal of the American Society of Nephrology. 17(11):3067-3075.
20. Zahid U, Ramachandran P, Spitalewitz S, Alasadi L, Chakraborti A, Azhar M, Mikhalina G, Sherazi A, Narh JT, Khattar P. 2020. Acute kidney injury in covid-19 patients: An inner city hospital experience and policy implications. American journal of nephrology. 51(10):786-796.
21. Zhang H, Pan J, Yao P, Hanqing H, Huilai M, Xie S. 2015. Investigation and response for the first case of group x meningococcal disease in zhejiang province. Chinese Journal of Preventive Medicine. 49(6):579-580.
22. Zhang J, Xie B, Hashimoto K. 2020. Current status of potential therapeutic candidates for the covid-19 crisis. Brain, behavior, and immunity. 87:59-73.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Bilal Javed
Institute of Zoology University of the Punjab, Lahore, Pakistan Email: bilaljaved345@live.com
Nabila Roohi
Institute of Zoology University of the Punjab, Lahore, Pakistan Email: nabila.zool@pu.edu.pk